Law360 (September 4, 2020, 5:39 PM EDT) -- Major drugmakers, attorneys general and pharma trade organizations have given the U.S. Food and Drug Administration conflicting arguments on whether patents for drug-device combinations and established risk evaluation and mitigation strategies should be added to the Orange Book.
The agency had asked for a variety of critiques about the generic-drug guide, which is turning 40 years old in October, and comments rolled in by the Aug. 31 deadline. When it comes to expanding what patents should be included, drug-device combinations are a particularly divisive area.
The idea of what to list is controversial because when a generic-drug company files an abbreviated...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!